Childhood nephrotic syndrome is a clinical entity characterized by massive loss of urinary protein (primarily albuminuria) leading to hypoproteinemia (hypoalbuminemia) and edema. The mechanism of development of childhood nephrotic syndrome is not yet clear. Kidney disease involves an interplay between inflammatory and biochemical changes with the development of innate immune response and accumulation and activation of leucocytes, particularly monocytes/macrophages in the kidney. The moncyte chemotactic protein-1 (MCP-1) is one of the CC chemokine family and it plays an important role in the recruitment of monocytes/macrophages into renal tubulointerstitium.
Introduction
Nephrotic syndrome is defined as heavy proteinuria severe enough to cause hypo-albuminemia, edema, and hypercholesterolemia. Although the molecular basis for this is still speculative, there is evidence that nephrotic syndrome may be a consequence of a primary glomerular defect, circulating factors, or an immunological abnormality. Most cases of idiopathic NS are steroid sensitive; nevertheless, some cases become steroid-resistant during their clinical course [1] . The development of kidney disease involves a complex interplay between neurohormonal, inflammatory and biochemical changes which act on renal cells. This can lead to the development of an innate immune response predominantly characterized by the accumulation and activation of leukocytes, particularly monocytes/macrophages, in the kidney. Chemokine-induced recruitment of peripheral leukocytes into tissues is a critical step in the development of inflammatory responses [ 2, 3, 4]. Chemokines are classified into 4 families according to the location of cysteine residues. The 4 chemokine groups are CC, C, CXC and CX3C, where C is a cysteine and X is any amino acid residues. [5] . The monocyte chemotactic protein-1 (MCP-1) is a member of the CC chemokine family, and a potent chemotactic factor for monocyte [6] . It plays an important role in the recruitment of monocytes/macrophages into renal tubulointerstitium.
Monocyte Chemo t Protein-1 (MCP-1) is produced by a variety of mesenchymal cells, including glomerular cells. Within the glomeruli there is MCP-1 overexpression in both crescent GN and nephrotic conditions. Local recruitment of monocytes is considered the predominant mechanism by which MCP-1 contributes to the renal damage [7] . It is also known to be produced by tubular epithelial cells in the kidney and to contribute to renal interstitial inflammation and fibrosis. Protein overload in renal tubular cells is shown to upregulate MCP-1 gene and its protein. These lines of evidence collectively suggest that increased urinary protein excretion probably aggravates renal tubular damage by enhancing MCP-1 expression in tubular cells [8] .
Detection of MCP-1 in renal tissues as well as in urine samples has been studied in various renal diseases. Monitoring chemokines in urine is a non-invasive procedure and may provide a more dynamic picture of the inflammatory state of the kidney than a biopsy. Urinary chemokines may have a great potential as a biomarker for renal diseases [4] .
Aim of the Work
The aim was to measure the urinary levels of MCP-1 in children with nephrotic syndrome and compare these levels in remission and relapse as well as in steroid sensitive and steroid resistant cases.
Patients and Methods

A-Patients:
The study was conducted in the Nephrology Clinic, Ain Shams University. It included 90 children, 70 of them are nephrotic patients following up at the clinic for at least one year, and 20 age and sex matched healthy children as a control group. The patients were 35 males and 35 females their ages ranged from 1-18 years. Patients with secondary nephrotic syndrome. All studied patients had been subjected to the following: 1-Detailed history taking laying stress on: Symptoms of nephrotic syndrome, duration of the disease, response to steroid therapy, other medications and complications of steroid therapy. 2-Careful clinical examination laying stress on: Detection of edema and signs of relapse and signs of therapy complications as cushingoid facies, straiae or hirsuitism.
3-Laboratory investigations including: A-Routine investigations for nephrotic syndrome including:
 Serum albumin.  Serum creatinine.  Serum cholesterol.  Complete urine analysis.  Urine protein/ creatinine ratio. B -Quantitative determination of urinary monocyte chemotactic protein-1 (MCP-1). Collection of blood samples: Venous blood sample, about 5 cc, was drawn from each subject and the usual precautions for puncture were observed and followed.
a. Blood samples were collected by a syringe with a wide bore needle 5ml. b. All samples were drawn from each subject under aseptic conditions. c. Evacuation of the sample after removal of the needle in clot activator test tube. d. Stored at room temperature for 20 minutes to 2 hours then centrifugation was done for plasma separation. e. Plasma was then collected at ependorph tube and frozen at -20 o C for storage till time of analysis. Collection of urine sample: Random mid stream urine samples were taken from patients and controls in clean containers at about 10am, complete urine analysis, urinary protein / creatnine ratio were done, and another sample was preserved at -20 °C till time of assay of MCP-1 level in urine.
Detailed laboratory methods:
a. Serum albumin, serum creatinine, serum cholesterol were measured by using Hitachi automatic analyzer 917. b. Complete urine analysis: dip sticks and microscopic examination.
c. Urine protein /creatinine ratio: It was estimated on Synchrone CX7 system employing a time end point colorimetric methods.
d. MCP-1 in urine: It was measured by ELISA.  Test principle for uMCP -1 This assay employs the quantitative sandwich enzyme immunoassay technique. A monoclonal antibody specific for MCP-1 has been pre-coated onto a microplate standard and samples are pipetted into the wells and any MCP -1 present is bounded by the immobilized antibody. After washing away any unbound substances, an enzyme linked polyclonal antibody specific for MCP -1 is added to the wells. Following a wash to remove any unbound antibodyenzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of MCP -1 bound in the initial step. The color development is stopped and the intensity of the color is measured.
Statistical Methods
Analysis of data was done by IBM computer using SPSS (statistical program for social science version 12). P value >0.05 insignificant-P value <0.05 significant-P value <0.01 highly significant 
Results:
The children included in the study were divided into 3
Group A N=35
Group C N=20
Group B N=35
Group C N=20 P
Least significant difference(LSD) post hoc test
Pr./cr. Table 2 : uMCP-1 levels in studied groups. 
Post hoc test (LSD) P Group C N=20
Group B N=35
Group
Discussion
Our study was designed to check urinary MCP-1 level in pediatric patients with idiopathic nephrotic syndrome, effect of remission and relapse on these levels as well as steroid response and to compare our results to the urinary levels of MCP-1 in age and sex matched control group. The current study findings showed that there was highly significant difference in urinary level of monocyte chemotactic protein-1 (MCP-1) between the studied groups where the urinary level of MCP-1 in children with nephrotic syndrome in relapse (group B) (322 ± 187 ug ∕ml) was markedly higher than patients in remission (group A) (102 ± 4.7ug ∕ml) and healthy controls (group c) (45 ± 20 ug ∕ml). Similar findings were also observed in previous studies. [1, 9] They observed that urinary excretion of MCP-1was significantly higher in idiopathic nephrotic syndrome (INS).Similarly a study reported high concentrations of MCP-1 in the urine of pediatric patients with minimal change nephrotic syndrome during relapse in comparison to patients in remission and normal healthy control.
[10] , [11] .
On the other hand, another study reported that urinary levels of MCP-1 were not significantly differernt between idiopathic nephrotic patients during remission and in relapse.
[12] This disagreement may be due to their small sample size or statistical disproportion between the number of relapse and remission cases. Also, in our study we found that MCP-1 level in urine of relapsed nephrotic patients (group B), nephrotic patients in remission (group A) and control subjects (group C) was not significantly correlated with other variables in these groups (serum cr., current age and gender) agreeing with another study that showed no correlation between uMCP-1 and age, gender and race among nephrotic patients and controls [9, 13].
Also, we found no significant difference in uMCP-1 levels among patients on different types of treatment. This result agreed with a study reporting that the increase of urinary chemokines (including MCP-1) in INS patients was independent of histology or response to corticosteroid therapy, [12] yet another study stated that the excretion of MCP-1 in children with MCD treated with Cs [11] . In the present study, MCP-1 level in urine of relapsed nephrotic patients (group B) was significantly highly positively correlated with Pr/Cr ratio, serum cholesterol and highly negatively correlated with serum albumin. This result is comparable to that observed before [11] and those reporting a significant negative correlation between urinary levels of MCP-1 and serum albumin and positive correlation to total serum cholesterol and triglycerides in chronic kidney diseases [14] . Also, MCP-1 level in urine of nephrotic patients in remission (group A) was significantly highly positively correlated with Pr/Cr ratio, serum cholesterol and highly negatively correlated with serum albumin. This agreed with previous studies stating that increased urinary protein excretion seems to contribute to the aggravation of renal tubulointerstitial lesions and the progression of renal diseases and increase the level of MCP-1 in the urine [8] . Similarly many studies showed that uMCP-1 levels positively correlated with albumin excretion rate. [15, 16, 17] . Previous studies suggested that increased urinary excretion of MCP-1 in the patients with glomerulopathy is probably due to the enhanced production of MCP-1 in renal tubules [18, 19] . The basolateral secretion of uMCP-1 is expected to be increased simultaneously when urinary MCP-1 excretion is increased induced by up-regulation of MCP-1 gene and its protein expression due to excessive exposure to plasma protein filtered from the damaged glomeruli [8].
Conclusion
Urinary MCP-1 is a highly sensitive and specific marker in INS yet our findings were not conclusive enough to establish a possibility of using urinary MCP-1 as a prognostic marker, pointing out particular steroid response, in INS. Further studies are obviously necessary to address this issue.
